CA
NZ
UK
AU
IND
US
…
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Net income | -13.72M | -15.59M | -8.40M | -10.49M | -9.08M |
| Selling general administrative | 6800.19M | 3.16M | 3.23M | 2.95M | 2.63M |
| Selling and marketing expenses | - | - | 3227.81M | - | - |
| Ebit | - | -31.75M | -8.40M | -10.54M | -9.13M |
| Ebitda | -13.72M | -15.59M | -8.40M | -10.54M | -9.13M |
| Depreciation and amortization | - | 16.16M | 8.83M | 0.02M | 0.05M |
| Operating income | -16.70M | -16.16M | -8.83M | -10.54M | -9.13M |
| Other operating expenses | 16.70M | 16.16M | 8.83M | 10.54M | 9.13M |
| Interest expense | - | - | - | -0.02M | 0.02M |
| Interest income | 2.99M | 0.40M | 0.34M | 0.02M | 0.02M |
| Net interest income | 2.99M | 0.40M | 0.34M | 0.02M | 0.02M |
| Income tax expense | - | - | -0.01M | -0.02M | -0.02M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 16.70M | 16.16M | 8.83M | 10.54M | 9.13M |
| Total other income expense net | 2.99M | 0.58M | 0.43M | 0.02M | 0.02M |
| Net income from continuing ops | -13.72M | -15.59M | -9.48M | -10.52M | -9.10M |
| Net income applicable to common shares | - | - | - | - | -9.10M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 140.72M | 60.29M | 7.35M | 13.23M | 20.52M |
| Other current assets | 0.06M | 0.08M | 0.07M | 0.05M | 0.22M |
| Total liab | 2.89M | 5.25M | 1.76M | 3.14M | 1.58M |
| Total stockholder equity | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M |
| Other current liab | 2732.50M | 3.00M | 1757.39M | - | 1.58M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -89.51M | -75.79M | -60.21M | -51.80M | -41.29M |
| Cash | 61.83M | 45.82M | 7.27M | 8.19M | 20.30M |
| Total current liabilities | 2.74M | 5.25M | 1.76M | 3.13M | 1.58M |
| Net debt | -61.68M | -45.82M | -7.27M | -8.18M | -20.30M |
| Short long term debt total | 0.15M | - | - | 0.01M | - |
| Other stockholder equity | 227.20M | 130.79M | 65.79M | 61.87M | 60.22M |
| Total current assets | 140.46M | 60.29M | 7.33M | 13.17M | 20.52M |
| Net tangible assets | - | - | - | - | 18.94M |
| Short term investments | 78.57M | 14.40M | 0.00M | 4.93M | - |
| Accounts payable | 2.74M | 2.25M | 1.76M | 3.13M | 1.58M |
| Accumulated other comprehensive income | 0.13M | 0.04M | -0.01M | 0.01M | -0.00M |
| Non currrent assets other | - | - | 0.00M | - | - |
| Non current assets total | 0.25M | 60230.78M | 0.01M | 0.06M | 0.00M |
| Capital lease obligations | 0.15M | 0.00M | 0.00M | 0.01M | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -63.45M | -14.34M | -2.96M | -4.92M | - |
| Change to liabilities | - | - | - | - | 0.40M |
| Total cashflows from investing activities | -63.45M | -14.34M | 4.93M | - | - |
| Total cash from financing activities | 91.57M | 59.29M | 2.03M | 0.03M | 10.88M |
| Change to operating activities | - | - | - | - | -0.09M |
| Net income | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Change in cash | 16.02M | 38.55M | -0.92M | -12.12M | 3.57M |
| Begin period cash flow | 45.82M | 7.27M | 8.19M | 20.30M | 16.74M |
| End period cash flow | 61.83M | 45.82M | 7.27M | 8.19M | 20.30M |
| Total cash from operating activities | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Issuance of capital stock | 127.14M | 59.40M | 1.84M | 0.11M | 10.93M |
| Depreciation | -716.46M | - | - | - | - |
| Sale purchase of stock | -35.00M | 0.00M | -0.00M | - | - |
| Other cashflows from financing activities | -1.13M | -0.10M | -0.05M | -0.08M | -0.05M |
| Change to netincome | - | - | - | - | 1.47M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -2.61M | 3.50M | -1.35M | 1.65M | 0.32M |
| Stock based compensation | 4.84M | 1.14M | 1.90M | 1.64M | 1.47M |
| Other non cash items | -0.72M | 4.54M | 1.90M | - | 9103214.90M |
| Free cash flow | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics Inc |
-1.97 2.67% |
71.78 | - | - | - | 5.56 | -2.42 |
| NVO Novo Nordisk A/S |
-0.68 1.64% |
40.70 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-3.02 0.55% |
547.85 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
916.06 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
| Name | Title | Year Born |
|---|---|---|
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, CEO, Pres & Director | 1984 |
| Ms. Kim R. Tsuchimoto CPA | CFO, Sec. & Treasurer | 1963 |
| Mr. Andrew J. Cittadine M.B.A. | Chief Operating Officer | 1972 |
| Dr. Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer | 1951 |
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | Co-Founder, CEO, President & Director | 1984 |
| Ms. Kim R. Tsuchimoto CPA | CFO, Secretary, Treasurer & Director | 1963 |
| Mr. Andrew J. Cittadine M.B.A. | Chief Operating Officer | 1973 |
| Dr. Christopher M. Starr Ph.D. | Co-Founder & Independent Executive Chairman of the Board | 1952 |
| Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. | Co-Founder, CEO, President & Director | 1984 |
| Mr. Quan Anh Vu | CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer | 1972 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.26%
Communication Services
-0.18%
Consumer Cyclical
-0.36%
Consumer Defensive
+0.07%
Energy
-0.01%
Financial Services
-0.26%
Financials
-2.20%
Healthcare
-0.55%
Industrials
-0.08%
Real Estate
-0.33%
Technology
-0.70%
Utilities
-0.41%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...